Focal therapy vs. surveillance for low-risk PCa

Article

Urology Times asked Scott Eggener, MD: How should urologists decide between focal therapy and active surveillance in men with low-risk prostate cancer?

Urology Times asked Scott Eggener, MD: How should urologists decide between focal therapy and active surveillance in men with low-risk prostate cancer? UT spoke with Dr. Eggener at the 2019 annual meeting in Chicago.

Related Videos
A panel of 5 experts on prostate cancer
A panel of 5 experts on prostate cancer
Paul E. Dato, MD, an expert on prostate cancer
Dr Daniel Allen Hamstra
Dr Daniel Allen Hamstra
Charles Parker, MD, answers a question during a Zoom video interview
Dr Daniel Allen Hamstra
Dr Daniel Allen Hamstra
© 2023 MJH Life Sciences

All rights reserved.